XML 116 R93.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Investments in Associates - Summary of Changes in Investments in Associates Accounted for Using Equity Method (Details) - CAD ($) $ in Thousands | 12 Months Ended
--- | ---
Mar. 31, 2018 | Mar. 31, 2017
Disclosure Of Significant Investments In Associates [Line Items] |  |
Beginning balance | $ 0 |
Additions | 64,689 |
Share of net (loss)/income | (1,473) | $ (50)
Interest income | (110) |
Ending balance | $ 63,106 | 0
Agripharm Corp. | Shares |  |
Disclosure Of Significant Investments In Associates [Line Items] |  |
Participating | 40.00% |
Beginning balance | $ 0 |
Additions | 38,711 |
Share of net (loss)/income | (232) |
Interest income | 0 |
Ending balance | $ 38,479 | 0
TerrAscend Corp | Shares |  |
Disclosure Of Significant Investments In Associates [Line Items] |  |
Participating | 24.00% |
Beginning balance | $ 0 |
Additions | 16,978 |
Share of net (loss)/income | (66) |
Interest income | 0 |
Ending balance | $ 16,912 | 0
Radicle Medical Marijuana Inc | Convertible Debenture |  |
Disclosure Of Significant Investments In Associates [Line Items] |  |
Participating | 23.80% |
Beginning balance | $ 0 |
Additions | 5,000 |
Share of net (loss)/income | (136) |
Interest income | (110) |
Ending balance | $ 4,754 | 0
Canopy Health Innovations Inc. | Shares |  |
Disclosure Of Significant Investments In Associates [Line Items] |  |
Participating | 43.00% |
Beginning balance | $ 0 |
Additions | 4,000 |
Share of net (loss)/income | (1,039) |
Interest income | 0 |
Ending balance | $ 2,961 | 0
Bedrocan Brasil S.A. | Shares |  |
Disclosure Of Significant Investments In Associates [Line Items] |  |
Participating | 39.80% |
Beginning balance | $ 0 |
Additions | 0 |
Share of net (loss)/income | 0 |
Interest income | 0 |
Ending balance | $ 0 | 0
Entourage Phytolab S.A. | Shares |  |
Disclosure Of Significant Investments In Associates [Line Items] |  |
Participating | 40.00% |
Beginning balance | $ 0 |
Additions | 0 |
Share of net (loss)/income | 0 |
Interest income | 0 |
Ending balance | $ 0 | $ 0

X
- Definition Investments in associates accounted for using equity method participating shares percentage. + References No definition available. + Details
Name: | cgc_InvestmentsInAssociatesAccountedForUsingEquityMethodParticipatingSharesPercentage
Namespace Prefix: | cgc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The total cost for the purchase of interests in investments accounted for using the equity method. + References No definition available. + Details
Name: | cgc_PurchaseCostOfInterestsInInvestmentsAccountedForUsingEquityMethod
Namespace Prefix: | cgc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of investments in associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2017-01-01 -Paragraph 55 -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_55&doctype=Standard -URIDate 2017-03-09 + Details
Name: | ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of income arising from interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2017-01-01 -Paragraph 23 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_23_c&doctype=Standard -URIDate 2017-03-09 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2017-01-01 -Paragraph 28 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_28_e&doctype=Standard -URIDate 2017-03-09 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Expiry date 2018-01-01 -Name IAS -Number 18 -IssueDate 2017-01-01 -Paragraph 35 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=18&date=2017-03-02&anchor=para_35_b_iii&doctype=Standard&book=B -URIDate 2017-03-09 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2017-01-01 -Paragraph B13 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2017-03-01&anchor=para_B13_e&doctype=Appendix&seq=2 -URIDate 2017-03-09 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2017-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_112_c&doctype=Standard -URIDate 2017-03-09 + Details
Name: | ifrs-full_RevenueFromInterest
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2017-01-01 -Paragraph 85 -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_85&doctype=Standard -URIDate 2017-03-09 + Details
Name: | ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=cgc_AgripharmCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=cgc_SharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=cgc_TerrAscendCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=cgc_RadicleMedicalMarijuanaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=cgc_ConvertibleDebentureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=cgc_CanopyHealthInnovationsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=cgc_BedrocanBrasilSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=cgc_EntouragePhytolabSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |